Skip to content

Replimune

US · REPL #3130 by market cap Listed 2018
19.07 -0.16 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

About Replimune

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Founded
2017
CEO
Dr. Sushil Patel, PhD
Employees
465
Headquarters
Woburn, Massachusetts, United States of America
Fiscal year end
03-31
Website
replimune.com

Company profile

Exchange
US
Symbol
REPL
Market-cap rank
#3130
Listing date
2018-07-20
Market cap
1.81B
Float cap
1.25B
Shares out
94.80M
Float shares
65.56M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.

Replimune discussion 0 comments

Add a comment